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ABSTRACT
In the world, there are many tests that allow the detection of HPV infection. These tests are based on different operating 
principles and have different levels of sensitivity. The first test to detect HPV infection was approved by the Food and 
Drug Administration in 2003. Since then, the FDA has approved five more commercial tests for this purpose, the last one 
in 2018. This paper discusses the principles of molecular tests to detect HPV, which have been approved by the FDA, the 
main differences between them, as well as their advantages and disadvantages. 
Key words: HPV detection; Hybrid Capture; Cervista; COBAS; Aptima; Onclarity
Ginekologia Polska 2019; 90, 2: 104–108
INTRODUCTION
Cervical cancer is currently the fourth most common 
cancer in terms of both incidence as well as mortality among 
women in the world [1]. According to estimated data, in 
2018 in the world, there were 570,000 new cases of this 
cancer and 311,000 deaths. However, in 28 countries, it is the 
most commonly diagnosed cancer among women, and in 
42 countries, it is the cancer with the highest mortality rate 
among women [1]. In Poland, cervical cancer now ranks sev-
enth in terms of cancer incidence and ninth as regards cancer 
mortality among women [2]. Main known etiological factors 
of cervical cancer are oncogenic types of human papilloma-
virus (HPV) [3]. HPV is a sexually transmitted virus. There are 
both high-oncogenic and low-oncogenic HPV types. The 
group of high-oncogenic types includes HPV –16, –18, –31, 
–33, –35, –39, –45, –51, –52, –56, –58 and –59 [4]. However, 
manufacturers of most commercial tests described here 
have also included the –66 and –68 types to high–risk (HR) 
types. In the further part of the publication, this classification 
will be adopted for simplification, however, these types are 
classified by the authors of the latest publications as probably 
(–66) and possibly (–68) carcinogenic [4]. The operation of 
molecular tests lies primarily in the detection of these types.
The important aspects in preventing the development of 
cervical cancer involve both cytological examination and the 
detection of HPV infection [5, 6]. The current guidelines of the 
Polish Society of Gynecologists and Obstetricians recommend 
performing an HPV test in case of obtaining an abnormal cytol-
ogy result (ASC-US, LSIL) as an alternative to a repeat cytology 
test [7]. There are many methods for detecting HPV infection, 
which we can divide into three main groups: nucleic acid hy-
bridization assays, signal amplification assays and nucleic acid 
amplification assays [5]. Until today, the Food and Drug Admin-
istration (FDA) has approved 7 tests detecting HPV infection: 
three signal amplification assays (Hybrid CaptureTM II genera-
tion, Cervista™ HPV HR, Cervista™ HPV 16/18) and four nucleic 
acid amplification assays (COBAS® HPV Test, Aptima™ HPV 
Assay, Aptima™ HPV 16 18/45 and BD Onclarity™ HPV Assay).
HYBRID CAPTURE
The first method for the detection of HPV infection reg-
istered by the FDA (2003) is a type of solution hybridiza-
tion followed by signal amplification, the Hybrid Capture II 
(HC2) generation method (Qiagen, Canada; former: Digene, 
USA) [8]. The materials to be examined are cervical swabs 
and biopsies [9]. The second-generation HC test allows to 
show the presence of 5 types of the virus with low oncogenic 
potential (HPV –6, –11, –42, –43, –44) and 13 types of the 
virus with high oncogenic potential (HPV –16, –18, –31, –33, 
–35, –39, –45, –51, –52, –56, –58, –59, –68).
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In the laboratory, the material is denatured in an alkaline 
environment [9] leading to lysis of cervical epithelial cells, 
viral capsid damage, release of HPV DNA and obtaining 
a single strand of viral DNA (Fig. 1A). The single strand of 
HPV DNA hybridizes with a specific RNA probe and, practi-
cally, with a mixture of RNA sequences complementary to 
HPV DNA of high or low oncogenic potential. The resulting 
RNA: DNA hybrids are captured and immobilized in wells 
of a microplate coated with antibodies against RNA:DNA 
hybrids. Then they are combined with a conjugate of an-
ti-hybrid antibodies with alkaline phosphatase. The addition 
of a chemiluminescent substrate (dioxetane) to the enzyme 
reaction triggers the emission of light proportional to the 
number of hybrids. The luminous intensity is measured in 
the luminometer and expressed in relative light units (RLU) 
in relation to the emission of positive control light. In order 
to eliminate false negative results caused by too little ma-
terial, the recommended cutoff value is 1.0 pg of viral DNA 
per 1 mL of the test sample, this value is similar for each of 
the HPV types detected [9]. This concentration is equivalent 
to 5,000 viral copies per assay or 100,000 copies/mL [10]. 
The advantages of the test are: the semi-quantitative 
evaluation of viral DNA in the infected cell and a relatively 
high sensitivity of the method, comparable to the amplifica-
tion reaction [11–13]. The method allows to distinguish virus 
types with high and low oncogenic potential but does not 
specify particular genotypes. The disadvantage of the test 
is also the occurrence of cross-reactions between the probe 
detecting HPV types with high oncogenic potential and 
other HPV viruses, the sequence of which do not contain 
a probe [14]. However, increasing the cutoff value to 10 pg of 
viral DNA per 1 mL eliminates the majority of cross reactions, 
except for reactions with HPV –53 and –67 [14]. From a clinical 
point of view, cross-reactions of the probe detecting types 
with high oncogenic potential with non-oncogenic types 
have practically no effect on the treatment of patients with 
cytological changes in the cervix [15]. Another disadvantage 
of the test is the possibility of false negative results when 
using some antifungal creams and contraceptive jelly [9].
The literature also reports on the existence of the Hy-
brid Capture III test, which was intended to remedy the 
cross-reactivity problem by using labeled oligonucleotides 
instead of antibodies against the DNA:RNA hybrids used in 
the HC2 test [16]. Although it has come into commercial 
use, the small literature defines it as a “non-commercial test” 
and states that it is sometimes used in scientific research in 
combination with the PCR reaction and the HC2 test [17].
CERVISTA
Other methods approved by the FDA (2009) are the 
Cervista™ HPV HR test and the Cervista™ HPV 16/18 test 
(Hologic Inc., USA). The materials for examination are cervi-
cal swabs [18], as well as biopsies [19].
The Cervista™ HPV HR test is based on solution hybridiza-
tion and is a qualitative test to detect DNA of all 14 types of 
HR HPV [18, 19]. The method uses the Cleavase enzyme and 
consists of two isothermal reactions: the primary one, i.e. the 
binding of oligonucleotides to the target sequence, and the 
secondary one, i.e. fluorescence generation [18]. In the primary 
reaction, two types of oligonucleotides are used: a probe oli-
gonucleotide comprising a sequence complementary only to 
the 5 ‘part of the target sequence and a non-complementary 
region to its further part and Invader® oligonucleotide, com-
plementary to the 3’ part of the target sequence (Fig. 1B). These 
oligonucleotides overlap with at least one nucleotide, so that 
when bound to the target sequence, a structure is created that 
is a substrate for the Cleavase enzyme. This enzyme cleaves 
Figure 1. Principles of molecular HPV tests (description in the 
relevant paragraphs): (A) Hybrid Capture; (B) Cervista; (C) COBAS 
vs. Onclarity detection and genotyping of HPV types – different 
colors are different fluorescent dyes; (D) Common steps in COBAS and 
Onclarity; (E) APTIMA; F — fluorophore; Q — quencher; IC — internal 
control; M — magnetic microparticle
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the non-complementary region and overlapping nucleotides 
from the oligonucleotide probe. In the secondary reaction, the 
cleaved fragment hybridizes to a FRET oligonucleotide with 
a hairpin structure. FRET oligonucleotide has a fluorophore 
and a quencher. The presence of the quencher eliminates the 
phenomenon of fluorescence, because its absorption spectrum 
coincides with the emission spectrum of the fluorophore [20].
The next sequence is created, which cleaves the Cleav-
ase enzyme, because in this case, nucleotides of the hybrid-
ized sequences overlap. Cleavase cleaves the FRET oligonu-
cleotide between the fluorophore and the quencher, which 
causes fluorescence emission [18]. The internal control of 
the test is the sequence encoding the histone 2 protein 
— the mixture of oligonucleotides also contains oligonu-
cleotides that bind to this sequence. For the method to 
detect the presence of viral DNA and prevent false negative 
results, 1,250–2,500 copies of DNA are required for virus 
types –16, –18, –31, –45, –52 and –56; 2,500–5,000 copies 
of DNA for types –33, –39, –51, –58, –59, –66 and –68; and 
5,000–7,500 copies for type –35 [18].
The Cervista™ HPV HR test is characterized by high 
analytical sensitivity, comparable to the sensitivity of the 
HC2 test [19]. Compared to the HC2 test, the advantages 
of the test are: the Cervista includes an internal control, 
requires lower sample volume and involves hands-free time, 
because there is a possibility for automation [21, 22]. Be-
cause the test requires a small-volume sample, the collected 
material can be used for a greater amount of analysis, e.g. 
for testing for other pathogens. The disadvantages of the 
test are: cross-reactivity with HPV types –67 and –70 and the 
possibility of false negative results when using contraceptive 
gels and antifungal creams. Like the HC2 method, Cervista 
is not specific for particular viral genotypes [18].
The Cervista™ HPV 16/18 test is based on the same re-
actions as the Cervista™ HPV HR test, however, it contains 
oligonucleotides complementary only to the two most 
oncogenic HPV strains: 16 and 18, so it is used to detect 
only these two types [23]. The test can be used alone or 
in combination with Cervista™ HPV HR, which is recom-
mended in the case of squamous cells with indeterminate 
significance (ASC-US) [21]. The advantages of the test are 
high analytical sensitivity and analytical specificity [24]. In 
comparison to the PCR method, the overall positive and 
negative percentages of compliance were 94% and 85%, 
respectively [24]. The disadvantage is the cross-reactivity 
with HPV 31; however, it only occurs at high concentrations 
of this genotype in the sample [21, 22]. 
COBAS
The COBAS® HPV (Roche Molecular Systems Inc., Swit-
zerland) was approved by the FDA in 2011. The material 
for examination is an LBC (liquid-based cytology) cervical 
swab [25]. The test contains primers that are used in the 
PCR reaction to amplify the sequence of about 200 nucleo-
tides of the gene encoding the L1 protein of 14 HR HPV 
types. Oligonucleotide primers are fluorescently labeled, 
allowing the use of quantitative PCR technology (qPCR). 
The reaction is automated and takes place in the dedicated 
COBAS x 480 instrument, which reduces the manual work 
required [25]. There are 4 fluorescent probes used: separate 
for HPV-16, for HPV-18, for the remaining 12 types, and for 
the beta-globin gene as positive control of human DNA 
isolation (Fig. 1C). The test is therefore differentiating only 
for HPV –16 and –18 genotypes. 
If L1 gene sequence of one or more HR HPV types is 
present in the sample, specific primers attach to the com-
plementary sequences and the amplification reaction 
takes place (Fig. 1D). Detection is based on oligonucleotide 
probes [26]. These probes are labeled at one end with a fluo-
rophore and at the other with a quencher. The quencher is 
so close to the fluorophore that no emission of fluorescence 
occurs. If the probe binds to a complementary sequence, 
then it will be degraded during the ongoing qPCR reaction, 
thanks to 5’–3’ exonuclease activity of polymerase.
Degradation of the probe causes separation of the 
fluorophore from the quencher, thanks to which the fluo-
rescence can be detected (for each marker at different ex-
citation wave) [26].
The detection limit (LoD) has been specified for 150 cop-
ies/mL for type –45, 300 copies/mL for types –16, –31, –33, 
–39, –51 and –59, 600 copies/mL for types –18, –35 and –58, 
1200 copies/ mL for types –56, –66 and –68 and 2400 cop-
ies/mL for type –52 [25].
The advantage of the test is its high sensitivity, com-
parable to the HC2 test [27]. The COBAS test shows lower 
cross-reactivity with non-oncogenic virus types than Hybrid 
Capture II (1.2% vs. 2.2%) [28]. The test does not cross-react 
with other microorganisms or interact with lubricants or 
antifungal drugs [25]. The COBAS test allows genotyping 
of only HPV –16 and –18 types. The remaining 12 types 
give the same signal, so they are detected together, and 
it is not possible to differentiate the type of virus. Another 
advantage mentioned above is automation, which reduces 
the need for manual work. The literature does not report 
any shortcomings of the test, however, the high price of 
the instrument used to conduct the test can certainly be 
regarded as a disadvantage.
APTIMA
The APTIMA (Gen-Probe, USA) test was approved by 
the FDA in 2011. The materials tested are ThinPrep cervi-
cal smears [29]. The tests are designed to detect mRNA of 
E6/E7 oncoproteins encoded in the viral genome. There 
are two variants of this test: APTIMA™ HPV and APTIMA™ 
107
Katarzyna Sitarz et al., FDA-approved HPV molecular tests
www. journals.viamedica.pl/ginekologia_polska
16 18/45 (approved by the FDA in 2012). APTIMA™ HPV 
detects an infection with 14 HR HPV types, while APTIMA™ 
16 18/45 detects an infection with three HPV oncogenic 
types: –16, –18 and/or –45. The tests do not allow to dis-
tinguish which of the detected types of infection occurred.
The APTIMA test consists of 3 stages, which are carried out 
in one tube: target capture; target amplification; detection of 
the amplification products [29]. At the beginning, samples are 
transferred to the Specimen Transport Medium, in which cell ly-
sis occurs and the mRNA contained therein is released (Fig. 1E). 
Then, target mRNAs bind to complementary oligonucleotides 
with (poly-deoxyadenosine) polyA tail. Next, these hybrids are 
bound by poly-deoxythymidine (polyT) molecules, attached to 
the magnetic microparticles. This makes it possible to separate 
the target mRNA with a magnet. The next step, amplification, 
is associated with using the TMA method, i.e. amplification 
of RNA using reverse transcriptase and T7 polymerase. The 
captured mRNAs are transcribed into complementary DNA 
by reverse transcriptase. The cDNA contains a promoter for 
the T7 RNA polymerase, which allows this enzyme to join the 
cDNA and create multiple copies of the complementary RNA 
strand. Detection of the resulting amplicons is done using the 
Hybridization Protection Assay. The assay involves hybridiza-
tion of duplicated sequences with fluorescently labeled oligo-
nucleotide probes. In the absence of hybridization, the probe is 
degraded by borate buffered solution containing a surfactant. 
Therefore, the fluorescence signal can be detected only in the 
presence of multiplication by T7 polymerase. Light emitted by 
hybrids is measured by RLU using a luminometer [29].
The LoD test, according to the manufacturer’s data, is 
less than 100 copies/reaction for types –16, –18, –31, –33, 
–35, –39, –45, –58, –59, –66, and –68, and between 100 and 
300 copies/reaction for types –51, –52 and –56. The reaction 
is carried out in a volume of 400 μL +/- 100 μL [29]. 
The sensitivity of the test is comparable to the sensi-
tivity of the HC2 test (according to Ratman et al., 96.3% 
for APTIMA vs 94.3% for Hybrid Capture II), so it is high, 
however, the greatest advantage of the test compared to 
HC2 is a higher correlation between a positive result of the 
test and pre-cancer/cervical cancer stages [30]. The test also 
has a higher specificity compared to the COBAS test [31]. 
A small disadvantage of the test is cross-reactivity with HPV 
types –26, –67, –70 and –82, however, it does not show 
cross-reactivity with other HPV strains or microorgan-
isms. Another disadvantage of the test is no genotyping 
of particular viral genotypes. The test interferes with some 
lubricants containing Polyquaternium 15, as well as with 
some antifungal agents containing tioconazole [29].
ONCLARITY
This test was approved by the FDA in 2018. The BD On-
clarity ™ HPV Assay (Becton, Dickinson and Company, USA) 
is based on qPCR [32]. The materials are cervical swabs col-
lected in a BD SurePath Preservative Fluid. BD Onclarity ™ 
HPV Assay detects E6/E7 oncogenes of 14 HPV HR types. The 
test is performed in three separate tubes (Fig. 1C). Onclarity 
test differentiates infection types –16, –18, –31, –45, –51 and 
–52 while the remaining 8 genotypes are detected as 3 dif-
ferent groups (–33/–58, –56/–59/–66 and 35/39/68) [32, 33]. 
The three tubes are necessary because the test uses 
15 probes (14 for viral sequences and 1 for the human beta 
globin gene sequence, as internal control), but only four 
fluorescent dyes are employed so each tube contains dif-
ferent probes labeled with the markers used. 
The test is fully automated and is divided into two stag-
es. The first stage consists in cell lysis and DNA isolation in 
a high pH environment [32, 33]. The second stage is based 
on TaqMan oligonucleotide probes, identically to the COBAS 
test (Fig. 1D). 
The LoD of the test is about 250 copies/mL for HPV–16, 
in the range of 800–900 copies/mL for HPV –31, –52 and –66, 
in the range of 1,000–1,500 copies/mL for types –18, –45, 
–56 and –59, in the range of 1,500–1,800 copies/mL for types 
–33, –35, –39 and –51 and in the range of 2,300–2,400 cop-
ies/mL for types –58 and –68 [32].
The advantages of the test are high specificity and sen-
sitivity, which are comparable to the HC2 test [34]. The test 
provides genotyping information for 6 types of HPV – this is 
the largest number out of all tests presented here. Thanks to 
full automation, the test is very easy to use and limits the work 
required [32]. There was also no cross-reactivity with other 
types of HPV or any microorganisms. As the only one of all 
FDA-accepted tests, it differentiates between 6 types of viral 
infection. The disadvantage of the test is the possibility of ob-
taining false negative results when using mucin, acyclovir and 
clindamycin [32]. Another downside is the high price of the 
BD Viper ™ LT system, which is necessary to perform the test.
SUMMARY
All molecular tests approved by the FDA have high sen-
sitivity and specificity. All tests detect 14 types of HPV HR, 
except for the HC2 test, which does not detect HPV-66, but 
does detect 5 low-oncogenic types. Cervista and APTIMA 
have variants that detect only types with the highest on-
cogenicity. The COBAS allows genotyping of HPV types 
–16 and –18, while Onclarity allows genotyping of types 
–16, –18, –31, –45, –51 and –52. The APTIMA test has the 
lowermost limit of detection among the tests described. The 
tests show cross-reactivity with low-risk HPV types, except 
for the Onclarity test, where cross-reactivity was not found. 
Cervista has the ability to be automated, and COBAS and 
Onclarity are compulsorily automated. Automation reduces 
the need to perform laboratory work, but the one-time 
expenditure for equipment is high. 
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The main disadvantage of the described tests is that they 
do not allow for observation of mixed infections as well as 
monitoring of persistent infection with all types belonging 
to the HPV HR group.
In comparison to cytological and histopathological tests, 
the molecular HPV tests described show different corre-
lations between pathological changes in the cervix and 
HPV-positive results. Differentiation of correlation between 
CIN2 + and positive HPV test result is as follows: HC2 test 
shows 93.4% detection of CIN2+ lesions, Cevrista HPV HR 
98.4%, Cervista HPV 16/18 77%, COBAS 95%, APTIMA HPV 
89.4%, Onclarity 98% [10, 21, 27, 30, 33, 35]. The literature 
does not provide this data for the APTIMA 16 16/45 test.
Each of the tests described has both advantages and 
disadvantages. It is important, therefore, that a laboratory 
that wants to carry out HPV detection tests selects the most 
suitable option for itself.
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